Business Context and Reporting Period
Company: Collegium Pharmaceutical, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 12, 2026
Reporting Period: Event-based report regarding an accelerated share repurchase agreement executed on August 12, 2026.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, or debt levels. The primary financial metric disclosed is the capital allocation for share repurchases:
- Repurchase Amount: $50 million committed under the Accelerated Share Repurchase (ASR) Agreement.
- Initial Shares Received: 1,556,420 shares.
- Reference Stock Price: $25.70 (closing price on August 12, 2026).
- Shares Outstanding: Approximately 32.5 million as of June 30, 2026.
- Liquidity Context: The transaction is funded from existing cash resources; specific cash balance figures are not provided in this filing.
Material Changes
The filing announces a material change in capital structure through the execution of an ASR Agreement with Jefferies LLC. This transaction is part of a broader $150 million share repurchase program authorized by the Board of Directors in July 2025. The initial delivery of shares represents approximately 80% of the total shares expected to be repurchased under this specific ASR agreement.
Guidance, Outlook, and Risks
Outlook and Settlement: The final number of shares to be repurchased will be determined based on the volume-weighted average price of the Company's common stock during the term of the agreement. Final settlement is expected to be completed no later than the fourth quarter of 2026.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Actual results may differ due to securities market developments, fluctuations in trading volume, and changes in the market price of the Company's common stock. The Company assumes no obligation to update these statements after the date of the filing.
Investor Verification Checklist
- Verify the final settlement date and total share count upon completion of the ASR in Q4 2026.
- Confirm the remaining balance available under the $150 million repurchase program authorized in July 2025.
- Review the Company's most recent 10-Q or 10-K for updated cash position and liquidity metrics to assess the impact of the $50 million outflow.
- Monitor the volume-weighted average price (VWAP) of the stock during the ASR term to estimate the final share count.